GRCE · Grace Therapeutics Inc
United States · RS rating 9 · As of 2026-10-14
| Price | 1.89 USD |
|---|---|
| 1-day change | -5.0% |
| RS rating (overall / 1M / 3M / 12M) | 9 / 15 / 18 / 18 |
| Stage | Basing |
| Composite / Minervini / CANSLIM score | 18 / 14 / 18 |
| Industry group (rank) | Medical-Biomed/Biotech (167) |
| EPS growth Q/Q | -133.3% |
| Sales growth Q/Q | – |
| Distance from 52-week high | +63.2% |
| Market cap (USD) | $36.4M |